Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rouissi K et al. - The authors found that NAT2 slow acetylator individuals temporarily carrying wild-type GSTT1 or GSTM1 null genotypes have a strong increased risk of bladder cancer. This cumulative effect was estimated at 12 for smokers harboring slow or an intermediate NAT2, GSTM1 null, and wild-type GSTT1 genotypes compared to non-smokers carrying rapid NAT2, wild-type GSTM,1 and GSTT1 null genotypes.

Related Articles

High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
BMC Cancer, 11/13/09    Relevance Score: 70%

Evidence-based Principles of Bladder Cancer and Diet
Urology, 10/21/09    Relevance Score: 70%

Incidence analyses of bladder cancer in the Nile delta region of Egypt
Cancer Epidemiology, 10/20/09    Relevance Score: 70%

Biomarkers in bladder cancer
BJU International, 10/01/09    Relevance Score: 70%

Diagnosis and Treatment of Bladder Cancer
American Family Physician, 10/01/09    Relevance Score: 70%

Today in Carcinogenesis...keeping you current

Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer
Clinical Cancer Research, 12/01/09

Activation of the hedgehog-signaling pathway in human cancer and the clinical implications
Oncogene, 11/30/09

Association of rare MSH6 variants with familial breast cancer
Breast Cancer Research and Treatment, 11/25/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address